Research on the mechanism of Carthamus tinctorius L. against skin fibrosis in systemic sclerosis based on serum pharmacochemistry, network pharmacology, and experimental validation | Synapse
March 3, 2026
Research on the mechanism of Carthamus tinctorius L. against skin fibrosis in systemic sclerosis based on serum pharmacochemistry, network pharmacology, and experimental validation
Puntos clave
Skin fibrosis is reduced by Carthamus tinctorius in systemic sclerosis victims, indicating its therapeutic potential.
The study identified key molecular pathways and biomarkers involved in this condition through network pharmacology analysis.
Experimental validation confirmed the effectiveness of serum pharmacochemistry derived from Carthamus tinctorius.
Findings suggest the need for further clinical evaluation of Carthamus tinctorius as a treatment option for skin fibrosis.